Royalty Pharma Plc

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BMVP7Y09
USD
39.15
-0.38 (-0.96%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Incyte Corp.
Alnylam Pharmaceuticals, Inc.
Zoetis, Inc.
Bristol Myers Squibb Co.
Vertex Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Royalty Pharma Plc
Walgreens Boots Alliance, Inc.
Viatris, Inc.
Horizon Therapeutics Plc
Seagen Inc.
Why is Royalty Pharma Plc ?
1
Poor long term growth as Operating profit has grown by an annual rate -6.93% of over the last 5 years
2
Negative results in Jun 25
  • OPERATING CASH FLOW(Y) Lowest at USD 2,520.18 MM
  • INTEREST(HY) At USD 133.93 MM has Grown at 43.63%
  • DEBT-EQUITY RATIO (HY) Highest at 116.18 %
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Royalty Pharma Plc for you?

Low Risk, High Return

Absolute
Risk Adjusted
Volatility
Royalty Pharma Plc
48.63%
1.71
25.95%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
3.58%
EBIT Growth (5y)
-6.93%
EBIT to Interest (avg)
7.51
Debt to EBITDA (avg)
3.87
Net Debt to Equity (avg)
0.97
Sales to Capital Employed (avg)
0.17
Tax Ratio
0
Dividend Payout Ratio
43.94%
Pledged Shares
0
Institutional Holding
81.14%
ROCE (avg)
12.61%
ROE (avg)
21.49%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
2.84
EV to EBIT
13.43
EV to EBITDA
13.43
EV to Capital Employed
1.93
EV to Sales
11.27
PEG Ratio
0.08
Dividend Yield
2.72%
ROCE (Latest)
14.39%
ROE (Latest)
26.82%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company
NET PROFIT(HY)

At USD 378.66 MM has Grown at 1,164.04%

DIVIDEND PAYOUT RATIO(Y)

Highest at 310.3%

DIVIDEND PER SHARE(HY)

Highest at USD 2.8

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

-25What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD 2,520.18 MM

INTEREST(HY)

At USD 133.93 MM has Grown at 43.63%

DEBT-EQUITY RATIO (HY)

Highest at 116.18 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.8 times

INTEREST COVERAGE RATIO(Q)

Lowest at 305.53

CASH AND EQV(HY)

Lowest at USD 1,744.93 MM

OPERATING PROFIT(Q)

Lowest at USD 209.8 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 36.26 %

PRE-TAX PROFIT(Q)

Lowest at USD 150.61 MM

NET PROFIT(Q)

Lowest at USD 90.15 MM

EPS(Q)

Lowest at USD 0.07

Here's what is working for Royalty Pharma Plc
Dividend per share
Highest at USD 2.8 and Grown
In each year in the last five years
MOJO Watch
Company is distributing higher dividend from profits generated

DPS (USD)

Dividend Payout Ratio
Highest at 310.3% and Grown
In each year in the last five years
MOJO Watch
Company is distributing higher proportion of profits generated as dividend

DPR (%)

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Royalty Pharma Plc
Pre-Tax Profit
At USD 150.61 MM has Fallen at -66.41%
over average net sales of the previous four periods of USD 448.39 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD 90.15 MM has Fallen at -67.74%
over average net sales of the previous four periods of USD 279.44 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow
Lowest at USD 2,520.18 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Interest Coverage Ratio
Lowest at 305.53
in the last five periods
MOJO Watch
The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Interest
At USD 133.93 MM has Grown at 43.63%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Debt-Equity Ratio
Highest at 116.18 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio
Lowest at 2.8 times and Fallen
In each half year in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Operating Profit
Lowest at USD 209.8 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin
Lowest at 36.26 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit
Lowest at USD 150.61 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD 90.15 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

EPS
Lowest at USD 0.07
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Cash and Eqv
Lowest at USD 1,744.93 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents